Th17 and Foxp3+ T regulatory cell dynamics and distribution in myelodysplastic syndromes

被引:69
作者
Bouchliou, Irene [1 ]
Miltiades, Paraskevi [1 ]
Nakou, Evangelia [1 ]
Spanoudakis, Emmanouil [1 ]
Goutzouvelidis, Aggelos [1 ]
Vakalopoulou, Sofia [2 ]
Garypidou, Vasilia [2 ]
Kotoula, Vasiliki [1 ]
Bourikas, George [1 ]
Tsatalas, Costas [1 ]
Kotsianidis, Ioannis [1 ]
机构
[1] Democritus Univ Thrace, Dept Hematol, Sch Med, Alexandroupolis, Greece
[2] Aristotle Univ Thessaloniki, Dept Internal Med, Propedeut Dept Internal Med 2, Thessaloniki, Greece
关键词
Tregs; Th17; cells; Myelodysplastic syndromes; Tumor immunity; TUMOR MICROENVIRONMENT; MULTIPLE-MYELOMA; IL-17; IMMUNITY; T(H)17; GROWTH; DISEASE; CANCER; INFLAMMATION; IMMUNOTHERAPY;
D O I
10.1016/j.clim.2011.03.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Foxp3(+) T regulatory cells (Tregs) and Th17 cells accumulate synchronously at tumor sites during cancer progression, where their interplay is apparently affecting the efficiency of the antitumor response. In myelodysplastic syndromes, a hematopoietic malignancy of myeloid origin, Tregs are highly increased in the late stages of the disease (L-MDS), but the mechanisms driving Treg expansion and the interaction between Treg and Th17 cell dynamics are still unknown. We demonstrate that the proliferative capacity of Tregs is deficient during the early MDS stages (E-MDS), while in L-MDS it returns to normal levels. In addition, synchronously to Treg expansion, L-MDS patients exhibit increased numbers of functionally competent bone marrow IL-17(+) and FOXP3(+)/IL-17(+) cells, in contrast to E-MDS patients, where Th17 cells are significantly decreased and hypofunctional. Our findings suggest similar kinetics of Treg and Th17 cells between MDS and solid tumors, indicating a common immune pathogenetic pathway between diverse cancer types. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:350 / 359
页数:10
相关论文
共 48 条
[11]   Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells [J].
Curti, Antonio ;
Pandolfi, Simona ;
Valzasina, Barbara ;
Aluigi, Michela ;
Isidori, Alessandro ;
Ferri, Elisa ;
Salvestrini, Valentina ;
Bonanno, Giuseppina ;
Rutella, Sergio ;
Durelli, Ilaria ;
Horenstein, Alberto L. ;
Fiore, Francesca ;
Massaia, Massimo ;
Colombo, Mario P. ;
Baccarani, Michele ;
Lemoli, Roberto M. .
BLOOD, 2007, 109 (07) :2871-2877
[12]   Rare-event analysis in flow cytometry [J].
Donnenberg, Albert D. ;
Donnenberg, Vera S. .
CLINICS IN LABORATORY MEDICINE, 2007, 27 (03) :627-+
[13]   Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients [J].
Ghiringhelli, Francois ;
Menard, Cedric ;
Puig, Pierre Emmanuel ;
Ladoire, Sylvain ;
Roux, Stephan ;
Martin, Francois ;
Solary, Eric ;
Le Cesne, Axel ;
Zitvogel, Laurence ;
Chauffert, Bruno .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (05) :641-648
[14]   Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome [J].
Gobert, Michael ;
Treilleux, Isabelle ;
Bendriss-Vermare, Nathalie ;
Bachelot, Thomas ;
Goddard-Leon, Sophie ;
Arfi, Vanessa ;
Biota, Cathy ;
Doffin, Anne Claire ;
Durand, Isabelle ;
Olive, Daniel ;
Perez, Solene ;
Pasqual, Nicolas ;
Faure, Christelle ;
Coquard, Isabelle Ray ;
Puisieux, Alain ;
Caux, Christophe ;
Blay, Jean-Yves ;
Menetrier-Caux, Christine .
CANCER RESEARCH, 2009, 69 (05) :2000-2009
[15]   Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis [J].
Guyot-Revol, V ;
Innes, JA ;
Hackforth, S ;
Hinks, T ;
Lalvani, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (07) :803-810
[16]   CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS) [J].
Kordasti, Shahram Y. ;
Ingram, Wendy ;
Hayden, Janet ;
Darling, David ;
Barber, Linda ;
Afzali, Behdad ;
Lombardi, Giovanna ;
Wlodarski, Marcin W. ;
Maciejewski, Jaroslaw P. ;
Farzaneh, Farzin ;
Mufti, Ghulam J. .
BLOOD, 2007, 110 (03) :847-850
[17]   IL-17-producing CD4+ T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome [J].
Kordasti, Shahram Y. ;
Afzali, Behdad ;
Lim, Ziyi ;
Ingram, Wendy ;
Hayden, Janet ;
Barber, Linda ;
Matthews, Katie ;
Chelliah, Rajani ;
Guinn, Barbara ;
Lombardi, Giovanna ;
Farzaneh, Farzin ;
Mufti, Ghulam J. .
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 (01) :64-72
[18]   Role of Stat3 in suppressing anti-tumor immunity [J].
Kortylewski, Marcin ;
Yu, Hua .
CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (02) :228-233
[19]   Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplasticsyndromes (MDS) [J].
Kotsianidis, I. ;
Bouchliou, I. ;
Nakou, E. ;
Spanoudakis, E. ;
Margaritis, D. ;
Christophoridou, A. V. ;
Anastasiades, A. ;
Tsigalou, C. ;
Bourikas, G. ;
Karadimitris, A. ;
Tsatalas, C. .
LEUKEMIA, 2009, 23 (03) :510-518
[20]   Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment [J].
Kryczek, Ilona ;
Wei, Shuang ;
Zou, Linhua ;
Altuwaijri, Saleh ;
Szeliga, Wojciech ;
Kolls, Jay ;
Chang, Alfred ;
Zou, Weiping .
JOURNAL OF IMMUNOLOGY, 2007, 178 (11) :6730-+